Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,523 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Breast cancer manifested by hematologic disorders.
Ishikawa T, Shimizu D, Kito A, Ota I, Sasaki T, Tanabe M, Yamada A, Arioka H, Shimizu S, Wakasugi J, Mori R, Chishima T, Ichikawa Y, Endo I. Ishikawa T, et al. Among authors: shimizu d, shimizu s. J Thorac Dis. 2012 Dec;4(6):650-4. doi: 10.3978/j.issn.2072-1439.2012.10.17. J Thorac Dis. 2012. PMID: 23205295 Free PMC article.
[Advances in breast cancer chemotherapy].
Ishikawa T, Shimizu S, Momiyama N, Ichikawa Y, Shimada H. Ishikawa T, et al. Among authors: shimizu s. Nihon Rinsho. 2006 Mar;64(3):529-35. Nihon Rinsho. 2006. PMID: 16529045 Review. Japanese.
Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan.
Ishikawa T, Shimizu S, Katayama K, Chishima T, Hamaguchi Y, Doi T, Tanabe M, Kasahara A, Yamaguchi N, Narui K, Ohta I, Matsumoto C, Shimizu D, Kito A, Suda T, Inaba M, Asaga T, Momiyama N, Ichikawa Y, Yoshimoto M, Morita S, Shimada H. Ishikawa T, et al. Among authors: shimizu d, shimizu s. Anticancer Res. 2009 May;29(5):1515-20. Anticancer Res. 2009. PMID: 19443359 Free article.
A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer.
Ishikawa T, Shimizu S, Inaba M, Asaga T, Katayama K, Fukuda M, Tokuda Y, Ishida K, Fukuma E, Suda T, Hamaguchi Y, Ishiyama A, Shimada H; Kanagawa Breast Cancer Treatment Society (KBCTS). Ishikawa T, et al. Among authors: shimizu s. Breast Cancer. 2004;11(4):374-9. doi: 10.1007/BF02968045. Breast Cancer. 2004. PMID: 15604993 Clinical Trial.
Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer.
Inari H, Suganuma N, Kawachi K, Yoshida T, Yamanaka T, Nakamura Y, Yoshihara M, Nakayama H, Masudo K, Oshima T, Yokose T, Rino Y, Shimizu S, Miyagi Y, Masuda M. Inari H, et al. Among authors: shimizu s. Breast Cancer. 2017 Nov;24(6):748-755. doi: 10.1007/s12282-017-0774-z. Epub 2017 Apr 19. Breast Cancer. 2017. PMID: 28425014
Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
Inari H, Suganuma N, Kawachi K, Yoshida T, Yamanaka T, Nakamura Y, Yoshihara M, Nakayama H, Yamanaka A, Masudo K, Oshima T, Yokose T, Rino Y, Shimizu S, Miyagi Y, Masuda M. Inari H, et al. Among authors: shimizu s. BMC Cancer. 2017 Feb 27;17(1):160. doi: 10.1186/s12885-017-3154-3. BMC Cancer. 2017. PMID: 28241804 Free PMC article.
4,523 results